Journal article
T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma
T Hilmenyuk, CA Ruckstuhl, M Hayoz, C Berchtold, JM Nuoffer, S Solanki, HC Keun, PA Beavis, C Riether, AF Ochsenbein
Oncoimmunology | TAYLOR & FRANCIS INC | Published : 2018
Open access
Abstract
A reduced immune surveillance due to immune deficiency or treatment with immunosuppressive drugs is associated with a higher risk to develop aggressive Non-Hodgkin's lymphoma (NHL). Nevertheless, NHL also develops in immunocompetent patients indicating an escape from the immune system. T cell function in advanced aggressive lymphoma is not well characterized and the molecular mechanisms how malignant B cells influence T cell function are ill-defined. We therefore studied T cell function in Eμ-myc transgenic mice that develop an aggressive B cell lymphoma with some similarities to human Burkitt-lymphoma (BL). In advanced lymphoma, the number of T cells was severely reduced and the remaining C..
View full abstractGrants
Funding Acknowledgements
We thank Andrea Huwiler for providing us with S1P, S1P Lyases and S1P receptor inhibitors as well for the determination of S1P levels in mouse serum and BCM by MS (Institute of Pharmacology, University of Bern); Thomas Kaufmann for providing us with QVD and other apoptosis inhibitors (Institute of Pharmacology, University of Bern) and Simon C. Robson for providing us CD39<SUP>-/-</SUP> mice (Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA). This work was supported by the Swiss National Science Foundation, the Swiss Cancer League, the Cancer League of the Canton of Bern, the Werner und Hedy Berger-Janser-Stiftung, the Bernese Foundation for Clinical Cancer Research and the Marlies Schwegler-Stiftung.